表紙
市場調査レポート

鎮痛剤市場の予測:主要企業の将来展望

Pain Relieving Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies

発行 Visiongain Ltd 商品コード 204742
出版日 ページ情報 英文 323 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.02円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
鎮痛剤市場の予測:主要企業の将来展望 Pain Relieving Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies
出版日: 2014年09月18日 ページ情報: 英文 323 Pages
概要

人口の高齢化および癌、関節炎、肥満などの病気は、鎮痛剤の売り上げを増加させると予測されています。世界全体の鎮痛剤市場における収益は2014年に682億米ドルに達する見込みです。

当レポートでは、世界の疼痛治療業界および市場の動向と収益予測、28の主力製品の収益見通しと競合、地域別市場、技術動向、参入企業の概要などをまとめ、お届けいたします。

第1章 調査概要

第2章 疼痛・疼痛管理のイントロダクション

  • 疼痛:感覚的・感情的現象
    • 疼痛の歴史的側面
    • 疼痛経路・痛みの原因
  • WHOの疼痛段階
    • 疼痛の分類
  • 慢性疼痛の心理的影響
    • 慢性的癌疼痛
    • 神経因性疼痛
    • 神経因性疼痛の識別
  • 疼痛の神経化学
    • プロスタグランジン
    • オピオイド
  • 疼痛管理薬
    • 疼痛治療におけるオピオイドの利用
    • OTC鎮痛薬
  • 市場定義

第3章 世界の鎮痛薬市場

  • 世界の鎮痛薬市場:市場概要
  • 世界の鎮痛薬市場
  • 世界の鎮痛薬市場:市場予測

第4章 麻薬性鎮痛薬市場:世界市場の分析と予測

  • 世界の麻薬性鎮痛薬市場
    • 市場予測
    • 市場シェアの変動:主要薬別
  • Opana ER (Endo Pharmaceuticals): 市場分析
    • 不正開封防止Opana ER製品
    • 売上実績の分析
    • 売上予測
  • Duragesic:売上実績の分析
    • 売上予測
  • Oxycontin ER:市場分析
    • 不正開封防止Oxycontin ER
    • 特許期限切れ・法廷闘争
    • 売上予測
  • Ultram:市場分析
    • 売上予測
  • Zaldiar/Ixprim:市場分析
    • 売上実績の分析
    • 売上予測
  • 世界のその他の麻酔薬市場予測
    • Subsys (Insys Therapeutics)
    • Oxecta (Pfizer)
    • 売上予測

第5章 非麻酔鎮痛薬市場:世界市場の分析と予測

  • 世界の非麻酔鎮痛薬市場
  • Aspirin (Bayer):市場分析
  • Panadol:市場分析
  • Advil:市場分析
  • Tylenol:市場分析
  • その他の非麻酔鎮痛薬市場

第6章 神経因性疼痛鎮痛薬:世界市場の分析と予測

  • 神経因性疼痛鎮痛のイントロダクション
    • 神経因性疼痛の識別
    • 神経因性疼痛の薬理学的介入
    • 世界の神経因性疼痛鎮痛薬市場
    • 世界の神経因性疼痛鎮痛薬:市場予測
    • 市場シェアの変動:主要薬別
  • Lidoderm:市場分析
  • Lyrica:市場分析
  • Cymbalta:市場分析
  • Neurontin:市場分析
  • Nucynta:市場分析
  • その他の神経因性疼痛鎮痛薬

第7章 抗片頭痛薬:世界市場の分析と予測

  • 片頭痛:イントロダクション
  • Relpax:市場分析
  • Maxalt:市場分析
  • Imitrex/Imigran:市場分析
  • Zomig:市場分析
  • Botox (Allergan): 市場分析
  • Treximet:市場分析
  • Axert:市場分析
  • その他の抗片頭痛鎮痛薬:売上予測
  • 抗片頭痛薬市場:将来の展望

第8章 抗関節炎薬:世界市場の分析と予測

  • 関節炎の理解:原因論・有病率
    • 関節炎状態の管理
    • 関節炎の治療に用いられる薬剤
  • Humira:市場分析
  • Enbrel:市場分析
  • Remicade:市場分析
  • Rituxan:市場分析
  • Celebrex:市場分析
  • Arcoxia:市場分析
  • その他の抗関節炎薬
  • 抗関節炎薬市場:将来の展望

第9章 主要国の鎮痛薬市場

  • 鎮痛薬市場:地域別
  • 主要国市場の予測
    • 市場シェアの変動:地域別
  • 地域別の鎮痛薬市場:分析・予測
  • 米国:最大のツン通訳市場
  • EU主要5カ国
    • EU主要5カ国市場:市場シェアの変動。国別
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
  • 日本
  • 中国
  • 韓国
  • ブラジル
  • インド
  • ロシア
  • トルコ
  • その他の鎮痛薬市場

第10章 鎮痛治療の研究開発パイプライン

  • 現在開発中の革新的製品が成長を促進する見込み
  • 麻薬性鎮痛薬の開発パイプライン
  • 非麻薬性鎮痛薬の開発パイプライン
  • 神経因性疼痛鎮痛薬の開発パイプライン
  • 抗片頭痛薬の開発パイプライン
  • 抗関節炎薬の開発パイプライン
  • 鎮痛薬R&Dの将来展望
  • 溶解性:薬剤開発の妨げ
  • モノクロナール抗体(MAb):新たな鎮痛薬が直面する課題の可能性
  • 新たなオピオイドが成長機会を提供
  • 鎮痛におけるカンナビノイド利用の可能性

第11章 世界の鎮痛薬市場の定性分析

  • 市場影響因子
  • SWOT分析
  • STEP分析

第12章 専門家の見解

第13章 結論

  • 市場概要
  • 特許および独占の終了の潜在的影響
  • 市場成長促進因子
  • 神経因性疼痛におけるアンメットニーズが成長の余地を残す
  • Botoxの認可は抗片頭痛薬市場を促進する予測
  • 新興市場は市場を前進させる
  • 将来の展望

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0007

Pain relieving drugs - new study showing you trends, R&D progress, and predicted revenues

Where is the pain relieving drugs market heading What are the commercial prospects for this market and related technologies See what the future holds for painkillers. Visiongain's new report shows you potential revenues and other trends to 2024, discussing data, opportunities and prospects.

Our 323 page report provides 265 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:

  • Dr Stephen K Doberstein, Senior Vice President and Chief Scientific Officer, Nektar Therapeutics
  • Dr Tom McCarthy, Chief Executive Officer, Spinifex Pharmaceuticals

You find prospects for key submarkets

In addition to analyses of the overall world market, you see revenue forecasts for these six submarkets to 2024:

  • Narcotic pain relieving drugs
  • Neuropathic pain relieving drugs
  • Treatments for arthritis
  • Non-Narcotic pain relieving drugs
  • Treatments for migraines
  • Other pain relieving drugs

Technologies that improve on the tolerance and dependence issues associated with pain relieving drugs will achieve success. The increasing use of abuse-resistant delivery systems in particular will be a major benefiting factor for pain relieving drugs as a whole.

Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products

How will leading drugs perform to 2024 at the world level Our study forecasts sales of 28 products including these brands:

  • Celebrex
  • Voltaren
  • Relpax
  • Lyrica
  • Cymbalta
  • Aspirin
  • Zomig
  • Duragesic
  • Oxycontin ER
  • Panadol
  • Lidoderm

Our study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines.

Discover how high revenues can go. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects for the leading regions and countries

Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for pain-treating products.

In addition to analyses of the overall world market, you discover individual revenue forecasts for 13 national markets to 2024:

  • US
  • Japan
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Brazil
  • Russia
  • India
  • China
  • Turkey
  • South Korea
  • Rest of the World

Our analyses show sustained growth, particularly for the BRIC nations of Brazil, Russia, India, and China. New product approvals and the development of abuse-resistant drugs will influence market growth.

Regulatory, demographic, and commercial developments worldwide will influence the markets both in the established North American and Western European economies, and the fast-rising emerging markets.

Research and development activities

What is happening in the R&D pipeline for pain relieving drugs You see developmental trends, gaining insight into the R&D pipeline for:

  • Narcotic pain relieving drugs
  • Neuropathic pain relieving drugs
  • Anti-Arthritis pain relieving drugs
  • Non-Narcotic pain relieving drugs
  • Anti-Migraine pain relieving drugs

What issues will affect the pain relieving drugs market

Our new report discusses issues and events affecting the pain relieving drugs market. You will find discussions of many issues and developments, including:

  • Reimbursement, regulations, patent expiries, generic competition and OTC switching
  • Cost savings and efficiencies
  • Anti-convulsants, analgesics, COX-2 inhibitors, novel opioids, cannabinoids and local anaesthetics
  • Overcoming drug tolerance and dependence
  • The use of biologics (e.g. monoclonal antibodies, MAbs,) for rheumatoid arthritis (RA)
  • Disease modifying anti-rheumatic drugs (DMARDs)
  • Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and aldose reductase inhibitors
  • Understanding pain pathways and mechanisms of action
  • Safety and patient compliance
  • Clinical evidence supporting product efficacy

Our investigation gives you multi-level business research and analyses with sales forecasts. You see how that industry and market can perform from 2014 to 2024.

Discussions of leading companies and prospects for market growth

What will happen next The pharmaceutical industry will improve treatments for pain relief and increase revenues from 2014 to 2024. The R&D pipeline is strong.

Overall world revenue for that market area will reach $68.2bn in 2014, our report forecasts. Aging populations and diseases such as cancer, arthritis and diabetes will increase sales of painkillers. Also, improved drug delivery and new formulations will be important.

You find discussions of Pfizer, GSK, Johnson & Johnson, Bristol-Myers Squibb and other developers and manufacturers. This decade, many opportunities will arise.

How the Pain Relieving Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies report helps you

In summary our 323 page report gives you the following knowledge:

  • Revenues forecast to 2024 for the overall pain relieving drugs market and 6 submarkets - discover the industry's prospects, finding promising technology areas for investments and revenues
  • Predicted revenues of 28 leading drugs to 2024 - discover prospects for the leading pain relieving drugs with forecasted revenues provided to 2024
  • Revenue forecasts to 2024 for 13 leading national markets - US, Japan, Germany, France, the UK, Italy, Spain, Brazil, Russia, India, China, Turkey, South Korea and Rest of the World
  • Assess leading companies - hear about products, results and strategies including recent activities and outlook for companies such as GSK, Johnson & Johnson, and Pfizer
  • Review of R&D pipelines - investigate developmental trends and progress
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market
  • View opinions from our survey, seeing interviews with industry authorities

You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the treatment of pain. You will find data, trends and predictions. Please order our report now.

Table of Contents

1. Report Overview

  • 1.1 Global Pain Relieving Drugs: Market Overview
  • 1.2 Global Pain Relieving Drugs Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. An Introduction to Pain and Pain Management

  • 2.1 Pain: A Sensory And Emotional Phenomenon
    • 2.1.1 Pain: A Short History
    • 2.1.2 Pain Pathways And The Origin Of Pain
  • 2.2 The World Health Organisation (WHO) Pain Ladder
    • 2.2.1 Classification Of Pain
      • 2.2.1.1 Acute Pain
      • 2.2.1.2 Chronic Pain
  • 2.3 The Psychosocial Effects Of Chronic Pain
    • 2.3.1 Chronic Cancer Pain
    • 2.3.2 Neuropathic Pain
    • 2.3.3 Identifying Neuropathic Pain
  • 2.4 The Neurochemistry Of Pain
    • 2.4.1 Prostaglandins
    • 2.4.2 Opioids
  • 2.5 Pain Management - A Brief Overview
  • 2.6 Pain Management Drugs
    • 2.6.1 The Use Of Opioids In Pain Treatment
    • 2.6.2 OTC Pain Relievers
  • 2.7 Market Definition

3. World Pain Relieving Drugs Market 2014-2024

  • 3.1 Global Pain Relieving Drugs: Market Overview
    • 3.1.1 Categorisation of the Global Pain Relieving Drug Market
    • 3.1.2 Pain Relieving Drugs: A Growing Market
  • 3.2 The Global Pain Relieving Drugs Market in 2013
    • 3.2.1 Market Dominance of Arthritic Pain Relieving Drugs
  • 3.3 Global Pain Relieving Drugs: Market Forecast 2014-2024
    • 3.3.1 Market Sectors That Will Drive Growth
    • 3.3.2 Abuse Deterrents and Safety Measures Will Boost Narcotic Pain Relieving Drugs Market Growth
    • 3.3.3 Changing Market Shares by Sector 2014-2024

4. Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024

  • 4.1 The Global Narcotic Pain Relieving Drugs Market in 2013
    • 4.1.1 Global Narcotic Pain Relieving Drugs: Market Forecast 2014-2024
    • 4.1.2 Changing Market Shares By Leading Drugs 2014-2024
  • 4.2 Opana ER (Endo Pharmaceuticals): Market Analysis
    • 4.2.1 Tamper-Proof Opana ER Products
    • 4.2.2 Opana ER: Historical Sales Analysis, 2014-2024
    • 4.2.3 Opana ER: Sales Forecast 2014-2024
    • 4.3 Duragesic: Market Analysis
  • 4.3.1 Duragesic: Historical Sales Analysis, 2011-2013
    • 4.3.2 Duragesic: Sales Forecast 2014-2024
  • 4.4 Oxycontin ER: Market Analysis
    • 4.4.1 Tamper Resistant Oxycontin ER
    • 4.4.2 Oxycontin ER: Patent Expiries and Legal Battles
    • 4.4.3 Oxycontin ER: Sales Forecast 2014-2024
  • 4.5 Ultram: Market Analysis
    • 4.5.1 Ultram: Sales Forecast 2014-2024
  • 4.6 Zaldiar/Ixprim: Market Analysis
    • 4.6.1 Zaldiar/Ixprim: Historical Sales Analysis, 2011-2013
    • 4.6.2 Zaldiar/Ixprim: Sales Forecast 2014-2024
  • 4.7 Other Narcotic Pain Relieving Drugs
    • 4.7.1 Subsys (Insys Therapeutics)
    • 4.7.2 Oxecta (Pfizer)
    • 4.7.3 Other Narcotic Pain Relieving Drugs: Sales Forecast 2014-2024

5. Non-Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024

  • 5.1 The Global Non-Narcotic Pain Relieving Drugs Market in 2013
    • 5.1.1 Global Non-Narcotic Pain Relieving Drugs: Market Forecast 2014-2024
    • 5.1.2 Changing Market Shares By Leading Drugs 2014-2024
  • 5.2 Aspirin (Bayer): Market Analysis
    • 5.2.1 Aspirin (Bayer): Historical Sales Analysis, 2010-2013
    • 5.2.2 Aspirin (Bayer): Sales Forecast 2014-2024
  • 5.3 Panadol: Market Analysis
    • 5.3.1 Panadol: Historical Sales Analysis, 2008-2013
    • 5.3.2 Panadol: Sales Forecast 2014-2024
  • 5.4 Advil: Market Analysis
    • 5.4.1 Advil: Historical Sales Analysis, 2012 and 2013
    • 5.4.2 Advil: Sales Forecast 2014-2024
  • 5.5 Tylenol: Market Analysis
    • 5.5.1 Tylenol: Sales Forecast 2014-2024
  • 5.6 Other Non-Narcotic Pain Drugs
    • 5.6.1 Exparel (Pacira Pharmaceuticals)
    • 5.6.2 Other Non-Narcotic Pain Drugs: Sales Forecast 2014-2024

6. Neuropathic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024

  • 6.1 An Introduction to Neuropathic Pain
    • 6.1.1 Identifying Neuropathic Pain
    • 6.1.2 Pharmacological Interventions for Neuropathic Pain
      • 6.1.2.1 Analgesics in Neuropathic Pain
      • 6.1.2.2 Anti-Convulsants
      • 6.1.2.3 Local Anaesthetics
      • 6.1.2.4 Anti-Depressants
      • 6.1.2.5 Aldose Reductase Inhibitors
    • 6.1.3 The Global Neuropathic Pain Relieving Drugs Market in 2013
    • 6.1.4 Global Neuropathic Pain Relieving Drugs: Market Forecast 2014-2024
    • 6.1.5 Changing Market Shares By Leading Drugs 2014-2024
  • 6.2 Lidoderm: Market Analysis
    • 6.2.1 Lidoderm Patent Expiry and Endo Pharma - Watson/Actavis Agreement
    • 6.2.2 Lidoderm Marketing Probe
    • 6.2.3 Lidoderm: Historical Sales Analysis, 2009-2013
    • 6.2.4 Lidoderm: Sales Forecast 2014-2024
  • 6.3 Lyrica: Market Analysis
    • 6.3.1 Lyrica: Historical Sales Analysis, 2009-2013
    • 6.3.2 Lyrica: Sales Forecast 2014-2024
  • 6.4 Cymbalta: Market Analysis
    • 6.4.1 Cymbalta: Historical Sales Analysis, 2008-2013
    • 6.4.2 Cymbalta: Sales Forecast 2014-2024
  • 6.5 Neurontin: Market Analysis
    • 6.5.1 Neurontin: Historical Sales Analysis, 2009-2013
    • 6.5.2 Neurontin: Sales Forecast 2014-2024
  • 6.6 Nucynta: Market Analysis
    • 6.6.1 Nucynta: Historical Sales Analysis, 2011-2013
    • 6.6.2 Nucynta: Sales Forecast 2014-2024
  • 6.7 Other Neuropathic Pain Relieving Drugs
    • 6.7.1 Retigabine (GSK; Valeant)
    • 6.7.2 Other Neuropathic Pain Relieving Drugs: Sales Forecast 2014-2024

7. Anti-Migraine Drugs: World Market Analysis and Forecast 2014-2024

  • 7.1 Migraine: An Introduction
    • 7.1.1 Management of Migraine
    • 7.1.2 Drugs Being Used In the Treatment of Migraine
    • 7.1.3 Other Migraine Relieving Techniques
    • 7.1.4 The Global Anti-Migraine Pain Relieving Drugs Market in 2013
    • 7.1.5 Global Anti-Migraine Pain Relieving Drugs: Market Forecast 2014-2024
    • 7.1.6 Changing Market Shares By Leading Drugs 2014-2024
  • 7.2 Relpax: Market Analysis
    • 7.2.1 Relpax: Historical Sales Analysis, 2009-2013
    • 7.2.2 Relpax: Sales Forecast 2014-2024
  • 7.3 Maxalt: Market Analysis
    • 7.3.1 Maxalt: Historical Sales Analysis, 2008-2013
    • 7.3.2 Maxalt: Sales Forecast 2014-2024
  • 7.4 Imitrex/Imigran: Market Analysis
    • 7.4.1 Imitrex/Imigran: Historical Sales Analysis, 2008-2013
    • 7.4.2 Imitrex/Imigran: Sales Forecast 2014-2024
  • 7.5 Zomig: Market Analysis
    • 7.5.1 Zomig: Licensing Transfers and Exclusivity
    • 7.5.2 Zomig: Historical Sales Analysis, 2009-2013
    • 7.5.3 Zomig: Sales Forecast 2014-2024
  • 7.6 Botox (Allergan): Market Analysis
    • 7.6.1 Botox: Historical Sales Analysis, 2009-2013
    • 7.6.2 Botox: Sales Forecast 2014-2024
  • 7.7 Treximet: Market Analysis
    • 7.7.1 Treximet: Agreements Between GSK, Pozen Pharmaceuticals and Pernix Therapeutics
    • 7.7.2 The Generic Treats to Treximet
    • 7.7.3 Treximet: Historical Sales Analysis, 2008-2013
    • 7.7.4 Treximet: Sales Forecast 2014-2024
  • 7.8 Axert: Market Analysis
    • 7.8.1 Axert: Historical Sales Analysis, 2011-2013
    • 7.8.2 Axert: Sales Forecast 2014-2024
  • 7.9 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast, 2014-2024
  • 7.10 Anti-Migraine Pain Relieving Drugs Market - Future Prospects
    • 7.10.1 Unmet Needs in the Treatment of Migraine

8. Anti-Arthritic Pain Drugs: World Market Analysis and Forecast 2014-2024

  • 8.1 Understanding Arthritis: An Introduction to its Aetiology and Prevalence
    • 8.1.1 Management of Arthritic Conditions
    • 8.1.2 Drugs Being Used In The Treatment Of Arthritis
    • 8.1.2.1 Analgesics As Pain Relieving Drugs
    • 8.1.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
    • 8.1.2.3 Corticosteroids
    • 8.1.2.4 Disease Modifying Anti-Rheumatic Drugs (DMARDS)
    • 8.1.3 Biological Drugs in the Treatment Of Arthritis
    • 8.1.3.1 Biologics Used for Rheumatoid Arthritis
    • 8.1.3.2 The Potential Side Effects of Biologics in the Treatment of Arthritis
    • 8.1.4 The Global Anti-Arthritis Pain Relieving Drugs Market in 2013
    • 8.1.5 Global Anti-Arthritis Pain Relieving Drugs: Market Forecast 2014-2024
    • 8.1.6 Changing Market Shares By Leading Drugs, 2014-2024
  • 8.2 Humira: Market Analysis
    • 8.2.1 Humira: Historical Sales Analysis, 2011-2013
    • 8.2.2 Humira: Sales Forecast 2014-2024
  • 8.3 Enbrel: Market Analysis
    • 8.3.1 Enbrel: Co-Promotions and Marketing Rights
    • 8.3.2 Enbrel: Historical Sales Analysis, 2008-2013
    • 8.3.3 Enbrel: Patent Expiries and Potential Competition, 2014-2024
    • 8.3.4 Enbrel: Sales Forecast 2014-2024
  • 8.4 Remicade: Market Analysis
    • 8.4.1 Remicade: Historical Sales Analysis, 2008-2013
    • 8.4.2 Remicade: Patent Expiries and Potential Competition, 2014-2024
    • 8.4.3 Remicade: Sales Forecast 2014-2024
  • 8.5 Voltaren: Market Analysis
    • 8.5.1 Voltaren: Historical Sales Analysis, 2008-2013
    • 8.5.2 Voltaren: Sales Forecast 2014-2024
  • 8.6 Rituxan (Rituximab, MabThera): Market Analysis
    • 8.6.1 Rituxan: Historical Sales Analysis, 2008-2013
    • 8.6.2 Rituxan: Patent Expiries and Potential Competition, 2014-2024
    • 8.6.3 Rituxan: Sales Forecast 2014-2024
  • 8.7 Celebrex: Market Analysis
    • 8.7.1 Celebrex: Historical Sales Analysis, 2008-2013
    • 8.7.2 Celebrex: Patents, Exclusivity, and Competition, 2014-2024
    • 8.7.3 Celebrex: Sales Forecast 2014-2024
  • 8.8 Arcoxia: Market Analysis
    • 8.8.1 Arcoxia: Historical Sales Analysis, 2008-2013
    • 8.8.2 Arcoxia: Sales Forecast 2014-2024
  • 8.9 Other Anti-Arthritis Pain Relieving Drugs
    • 8.9.1 Duexa (Horizon Pharma)
    • 8.9.2 Lodotra/RAYOS (Horizon Pharma; SkyePharma)
    • 8.9.3 Ofatumumab (Genmab, GSK)
    • 8.9.4 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast 2014-2024
  • 8.10 Anti-Arthritic Pain Relieving Drug Market - Future Prospects

9. Leading National Markets for Pain Relieving Drugs 2014-2024

  • 9.1 The Pain Relieving Drug Market By Region
    • 9.1.1 The Global Distribution of Pain Relieving Drugs In 2013
  • 9.2 Leading National Markets: Forecast, 2014-2024
    • 9.2.1 Changing Market Shares By Region, 2014-2024
  • 9.3 Regional Pain Relieving Drugs Markets: Analysis and Forecasts, 2014-2024
  • 9.4 United States: The Largest Pain Relieving Drug Market
  • 9.5 The EU5 Markets
    • 9.5.1 EU5 Markets: Changing Market Shares by Country, 2014-2024
    • 9.5.2 Germany
    • 9.5.3 UK
    • 9.5.4 France
    • 9.5.5 Italy
    • 9.5.6 Spain
  • 9.6 Japan
  • 9.7 China
  • 9.8 South Korea
  • 9.9 Brazil
  • 9.10 India
  • 9.11 Russia
  • 9.12 Turkey
  • 9.13 Rest of the World

10. Pain Relieving Drugs: R&D Pipeline 2014-2024

  • 10.1 Innovative Products Currently In Development Will Drive Growth
    • 10.1.1 Large Developmental Pipelines Encouraged By High Potential Growth
  • 10.2 Development Pipeline For Narcotic Pain Relieving Drugs, 2014
    • 10.2.1 Remoxy (Durect, Pain Therapeutics, Pfizer)
    • 10.2.2 MoxDuo IR (Shire; China Aoxing; QRxPharma)
    • 10.2.3 ALO-02 (Pfizer)
    • 10.2.4 DETERx - COL-003 (Collegium Pharmaceuticals)
    • 10.2.5 Acurox (Acura; Pfizer)
    • 10.2.6 Morphine-6-Glucuronide (Paion)
    • 10.2.7 Acuracet (Acura)
    • 10.2.8 ARX-02 (AcelRx Pharmaceuticals)
    • 10.2.9 Zohydro ER (Zogenix)
    • 10.2.10 BEMA Buprenorphine (BioDelivery Sciences; Endo Pharmaceuticals)
  • 10.3 Development Pipeline For Non-Narcotic Pain Relieving Drugs, 2014
    • 10.3.1 Lofexidine Hydrochloride (US World Meds)
    • 10.3.2 Synera (Nuvo Research)
    • 10.3.3 Neosaxitoxin (Proteus SA; Boston Children Hospital)
    • 10.3.4 OMS103 (Omeros)
    • 10.3.5 Tetrodotoxin (CK Life Sciences; WEX Pharmaceuticals)
  • 10.4 Development Pipeline For Neuropathic Pain Relieving Drugs, 2014
    • 10.4.1 Perampanel (Eisai)
    • 10.4.2 Serenbotase (Syntaxin, Ipsen, Allergan)
    • 10.4.3 EMA401 (Spinifex Pharmaceuticals)
    • 10.4.4 Ralfinamide (Newron)
    • 10.4.5 NT-11624 (Neurotune)
    • 10.4.6 AmiKet (Immune Pharmaceuticals)
    • 10.4.7 Eladur (Durect; Impax Laboratories)
    • 10.4.8 Clonidine Gel (Arcion Therapeutics; BioDelivery Sciences)
    • 10.4.9 AVP-923 (Avanir Pharmaceuticals)
    • 10.4.10 ARC-2022 (Arcion Therapeutics)
  • 10.5 Development Pipeline For Anti-Migraine Pain Relieving Drugs, 2014
    • 10.5.1 Zecuity (NuPathe; Teva)
    • 10.5.2 Lasmiditan (CoLucid Pharmaceuticals)
    • 10.5.3 NXN-188 (NeurAxon)
    • 10.5.4 Levadex/Semprana (Allergan)
  • 10.6 Development Pipeline For Anti-Arthritis Pain Relieving Drugs, 2014
    • 10.6.1 Zavryl/Ibuprofen-PC (PLx Pharma)
    • 10.6.2 Naproxcinod (NicOx)
    • 10.6.3 Xeljanz (Pfizer)
    • 10.6.4 Masitinib (AB Science)
    • 10.6.5 Belimumab (GSK, Human Genome Sciences)
  • 10.7 What Does the Future Hold for Pain Relieving Drugs Research and Development
  • 10.8 Solubility: A Hindrance To Drug Development
  • 10.9 Monoclonal Antibodies (MAbs) - Potential Novel Pain Drugs Facing Challenges
  • 10.10 New Opioids Providing Opportunities For Growth
  • 10.11 The Potential Use Of Cannabinoids In Pain Relief

11. Qualitative Analysis for the Global Pain Relieving Drugs Market 2014-2024

  • 11.1 Market Factors Influencing The Pain Relieving Drugs Market
  • 11.2 SWOT Analysis Of The Pain Relieving Drugs Market, 2014-2024
    • 11.2.1 Strengths
      • 11.2.1.1 Cost Effectiveness: A Major Driver for Growth
      • 11.2.1.2 Promising Candidates In The R&D Pipeline
    • 11.2.2 Weaknesses
      • 11.2.2.1 Product Withdrawals And Slow Regulatory Approvals
      • 11.2.2.2 Concerns Over Drug Side Effects
      • 11.2.2.3 Education In Pain Management Is A Key Unmet Need
    • 11.2.3 Opportunities
      • 11.2.3.1 Reformulations Of Existing Drugs Will Drive Market Growth
      • 11.2.3.2 Reforms In Narcotics Offer Growth Opportunities
      • 11.2.3.3 Ageing Population - Growth Driver For Pain Relieving Drugs
      • 11.2.3.4 The Economic Benefits Of Expansion Into Emerging Markets
      • 11.2.3.5 OTC Switching May Help To Delay Generic Erosion
    • 11.2.4 Threats
      • 11.2.4.1 Patent Expiries Will Lead To Generic Competition
      • 11.2.4.2 Regulatory And Pricing Scrutiny Could Suffocate Market Growth
      • 11.2.4.3 Inadequate Reimbursement Levels: A Potential Restraint On Market Growth
  • 11.3 STEP Analysis Of The Pain Relieving Drugs Market, 2014-2024
    • 11.3.1 Social Factors Affecting The Pain Relieving Drugs Market
    • 11.3.2 Technological Factors Affecting the Pain Relieving Drugs Market
    • 11.3.3 Economic Factors Affecting The Pain Relieving Drugs Market
    • 11.3.4 Political Factors Affecting The Pain Relieving Drugs Market

12. Expert Opinions

  • 12.1 Interview With Dr Stephen K Doberstein, Senior Vice President And Chief Scientific Officer, Nektar Therapeutics
    • 12.1.1 Pain Relieving Drugs: Current Trends In The Market
    • 12.1.2 Nektar's NKTR-181 Product And Its Mechanism To Mitigate Against Opioid Abuse
    • 12.1.3 Key Developments In Pain Management And The Steps Being Taken To Reduce Addiction To Pain Drugs
    • 12.1.4 Nektar's Development Programme And Issues Around Penetration Of The Blood-Brain Barrier
    • 12.1.5 Future Expansion Plans
    • 12.1.6 On The Unmet Need For Abuse-Resistant And Highly Efficacious Pain Relieving Drugs
    • 12.1.7 On The Developments Expected To Enter The Market In The Coming Years And The Need To Re-invent Known Classes Of Analgesic Molecules
  • 12.2 Interview With Dr Tom McCarthy, Chief Executive Officer, Spinifex Pharmaceuticals
    • 12.2.1 The Quest For Alternative Pain Relief Therapies
    • 12.2.2 The Future Potential Of Combination Therapies In Pain Relief
    • 12.2.3 On Developing, Validating and Demonstrating The Clinical Potential Of Novel Mechanisms For Tackling Pain
    • 12.2.4 On The Market Potential Of Spinifex's EMA401 Product
    • 12.2.5 On Expansion Plans For EMA401 And Pain Relief As A Whole
    • 12.2.6 The Drug Development And Commercialisation Challenges Facing The Pain Relieving Drugs Market
    • 12.2.7 Future Outlook On The Market And The Potential For Novel Analgesics

13. Conclusions

  • 13.1 Market Overview
  • 13.2 The Likely Impacts Of Patent And Exclusivity Expiries On Pain Relieving Drugs
  • 13.3 Major Growth Drivers For Pain Relieving Drugs
  • 13.4 Under-Served Needs In Neuropathic Pain Leaves Room For Growth
  • 13.5 The Narcotic Pain Relieving Drugs Market: Its Driving And Restraining Factors
  • 13.6 Botox Approval Expected To Boost Anti-Migraine Submarket
  • 13.7 The Rise Of Biological Anti-Arthritic Pain Drugs
  • 13.8 Emerging Markets Set To Drive Steer Market Forward
  • 13.9 What Does The Future Hold For Pain Relieving Drugs

List of Tables

  • Table 1.1 Italian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 1.2 Global Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2024
  • Table 2.1 Comparison of Acute and Chronic Pain
  • Table 2.2 Therapeutic Classes In Pain Management
  • Table 3.1 The Global Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2013
  • Table 3.2 The Global Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2013-2024
  • Table 3.3 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2013-2018, 2018-2024, 2013-2024
  • Table 3.4 The Global Pain Relieving Drugs Market: Revenue ($m) by Sector, 2013, 2018, 2024
  • Table 3.5 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2013, 2018, 2024
  • Table 4.1 The Global Narcotic Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
  • Table 4.2 The Global Narcotic Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
  • Table 4.3 The Narcotic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
  • Table 4.4 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
  • Table 4.5 Opana ER: Historical Sales ($m, AGR%), 2011-2013
  • Table 4.6 Opana ER: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 4.7 Duragesic: Historical Sales ($m, AGR%), 2011-2013
  • Table 4.8 Duragesic: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 4.9 Oxycontin: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 4.10 Ultram: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 4.11 Zaldiar/Ixprim: Historical Sales ($m, mEuros, AGR%), 2010-2013
  • Table 4.12 Zaldiar/Ixprim: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 4.13 Other Narcotic Pain Relieving Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 5.1 The Global Non-Narcotic Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
  • Table 5.2 The Global Non-Narcotic Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
  • Table 5.3 The Non-Narcotic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
  • Table 5.4 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
  • Table 5.5 Aspirin and Aspirin Cardio: Historical Sales ($m, mEuros, AGR%), 2010-2013
  • Table 5.6 Aspirin (Bayer): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 5.7 Panadol Formulations, 2014
  • Table 5.8 Panadol (GSK): Historical Sales ($m, £m, AGR%), 2008-2013
  • Table 5.9 Panadol (GSK): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 5.10 Selected Advil Products and Product Details, 2014
  • Table 5.11 Advil: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 5.12 Selected Tylenol Products and Product Details, 2014
  • Table 5.13 Tylenol: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 5.14 Other Non-Narcotic Pain Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 6.1 Key Drug Indications for Neuropathic Pain, 2014
  • Table 6.2 FDA-Approved Drugs Indicated for Neuropathic Pain, 2014
  • Table 6.3 The Global Neuropathic Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
  • Table 6.4 The Global Neuropathic Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
  • Table 6.5 The Neuropathic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
  • Table 6.6 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
  • Table 6.7 Lidoderm: Historical Sales ($m, AGR%), 2009-2013
  • Table 6.8 Lidoderm: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 6.9 Lyrica: Historical Sales ($m, AGR%), 2009-2013
  • Table 6.10 Lyrica: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 6.11 Cymbalta: Historical Sales ($m, AGR%), 2008-2013
  • Table 6.12 Cymbalta: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 6.13 Neurontin: Historical Sales ($m, AGR%), 2009-2013
  • Table 6.14 Neurontin: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 6.15 Nucynta: Historical Sales ($m, AGR%), 2010-2013
  • Table 6.16 Nucynta: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 6.17 Other Neuropathic Pain Relieving Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.1 The Global Anti-Migraine Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
  • Table 7.2 The Global Anti-Migraine Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
  • Table 7.3 The Anti-Migraine Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
  • Table 7.4 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
  • Table 7.5 Relpax: Historical Sales ($m, AGR%), 2009-2013
  • Table 7.6 Relpax: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.7 Maxalt: Historical Sales ($m, AGR%), 2008-2013
  • Table 7.8 Maxalt: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.9 Imitrex/Imigran: Historical Sales ($m, £m, AGR%), 2008-2013
  • Table 7.10 Imitrex/Imigran: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.11 Zomig: Historical Sales ($m, AGR%), 2009-2013
  • Table 7.12 Zomig: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.13 Botox (Allergan): Historical Sales ($m, AGR%), 2009-2013
  • Table 7.14 Botox: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.15 Treximet: Historical Sales ($m, AGR%), 2008-2013
  • Table 7.16 Treximet: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.17 Axert: Historical Sales ($m, AGR%), 2011-2013
  • Table 7.18 Axert: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.19 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 8.1 Selected Examples of Anti-Arthritic Pain Relieving Drugs, 2014
  • Table 8.2 The Global Anti-Arthritic Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
  • Table 8.3 The Global Anti-Arthritis Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
  • Table 8.4 The Anti-Arthritis Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
  • Table 8.5 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
  • Table 8.6 Humira: Historical Sales ($m, AGR%), 2010-2013
  • Table 8.7 Humira: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 8.8 Enbrel: Historical Sales ($m,bn Yen, AGR%) by Company, 2008-2013
  • Table 8.9 Enbrel: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 8.10 Remicade: Historical Sales ($m, bn Yen, AGR%) by Company, 2008-2013
  • Table 8.11 Remicade: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 8.12 Voltaren: Historical Sales ($m, AGR%), 2008-2013
  • Table 8.13 Voltaren: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 8.14 Rituxan: Historical Sales ($m, bn Yen, AGR%), 2008-2013
  • Table 8.15 Rituxan: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 8.16 Celebrex: Historical Sales ($m, AGR%), 2008-2013
  • Table 8.17 Celebrex: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 8.18 Arcoxia: Historical Sales ($m, AGR%), 2008-2013
  • Table 8.19 Arcoxia: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 8.20 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.1 The Global Pain Relieving Drugs Market: Market Size ($m) and Market Share (%) by Region, 2013
  • Table 9.2 Global Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2024
  • Table 9.3 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2013-2018, 2018-2024, and 2013-2024
  • Table 9.4 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2013, 2018, 2024
  • Table 9.5 US Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.6 US Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.7 The EU5 Pain Relieving Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2013-2024
  • Table 9.8 The EU5 Pain Relieving Drugs Market: Revenue ($m) and Market Share (%) by Country, 2013
  • Table 9.9 EU5 Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.10 The EU5 Pain Relieving Drugs Market: Market Share (%) by Country, 2013, 2018, 2024
  • Table 9.11 The German Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.12 The German Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.13 The UK Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.14 The UK Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.15 French Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.16 French Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.17 Italian Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.18 Italian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.19 Spanish Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.20 Spanish Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.21 Japanese Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.22 Japanese Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.23 Chinese Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.24 Chinese Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.25 South Korean Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.26 South Korean Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.27 Brazilian Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.28 Brazilian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.29 Indian Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.30 Indian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.31 Russian Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.32 Russian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.33 Turkish Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.34 Turkish Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.35 Rest of the World Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 9.36 Rest of the World Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 10.1 R&D Pipeline for Narcotic Pain Relieving Drugs, 2014
  • Table 10.2 R&D Pipeline for Non-Narcotic Pain Relieving Drugs, 2014
  • Table 10.3 R&D Pipeline for Neuropathic Pain Relieving Drugs, 2014
  • Table 10.4 R&D Pipeline for Anti-Migraine Pain Relieving Drugs, 2014
  • Table 10.5 R&D Pipeline for Anti-Arthritis Pain Relieving Drugs, 2014
  • Table 11.1 Pain Relieving Drugs: Market Drivers and Restraints 2014-2024
  • Table 11.2 SWOT Analysis of the Pain Relieving Drugs Market, 2014-2024
  • Table 11.3 Global Population Forecast: Total Population (bn, CAGR %) and Over-65 Population (bn, CAGR%), 2012, 2015, 2018, 2023
  • Table 11.4 STEP Analysis of the Pain Relieving Drugs Market, 2014-2024
  • Table 13.1 Pain Relieving Drugs: Market Forecast ($m, CAGR%), 2013, 2018, 2021, 2024
  • Table 13.2 Pain Relieving Drugs: Market Forecast ($m) by Sector, 2013, 2018, 2021, 2024
  • Table 13.3 Global Pain Relieving Drugs: Market Shares (%) by Region, 2013, 2018, 2021, 2024

List of Figures

  • Figure 1.1 Global Population Forecast: Total Population (bn) and Over-65 Population (bn), 2012, 2015, 2018, and 2023
  • Figure 1.2 Global Pain Relieving Drugs Market: Submarkets, 2014
  • Figure 2.1 Categories of Pain
  • Figure 3.1 The Global Pain Relieving Drugs Market: Revenue ($m) by Sector, 2013
  • Figure 3.2 The Global Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 3.3 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2013-2018
  • Figure 3.4 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2018-2024
  • Figure 3.5 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2013-2024
  • Figure 3.6 The Global Pain Relieving Drugs Market: Revenue ($m) by Sector, 2013, 2018, 2024
  • Figure 3.7 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2013
  • Figure 3.8 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2018
  • Figure 3.9 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2024
  • Figure 4.1 The Global Narcotic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013
  • Figure 4.2 The Global Narcotic Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 4.3 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013
  • Figure 4.4 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2018
  • Figure 4.5 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2024
  • Figure 4.6 Opana ER: Historical Sales ($m, AGR%), 2011-2013
  • Figure 4.7 Opana ER: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 4.8 Duragesic: Historical Sales ($m, AGR%), 2011-2013
  • Figure 4.9 Duragesic: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 4.10 Oxycontin: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 4.11 Ultram: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 4.12 Zaldiar/Ixprim: Historical Sales (mEuros, AGR%), 2010-2013
  • Figure 4.13 Zaldiar/Ixprim: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 4.14 Other Narcotic Pain Relieving Drugs: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 5.1 The Global Non-Narcotic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013
  • Figure 5.2 The Global Non-Narcotic Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 5.3 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013
  • Figure 5.4 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2018
  • Figure 5.5 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2024
  • Figure 5.6 Aspirin and Aspirin Cardio: Historical Sales (mEuros, AGR%), 2010-2013
  • Figure 5.7 Aspirin (Bayer): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 5.8 Panadol (GSK): Historical Sales (£m, AGR%), 2008-2013
  • Figure 5.9 Panadol (GSK): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 5.10 Advil: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 5.11 Tylenol: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 5.12 Other Non-Narcotic Pain Drugs: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 6.1 The Global Neuropathic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013
  • Figure 6.2 The Global Neuropathic Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 6.3 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013
  • Figure 6.4 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2018
  • Figure 6.5 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2024
  • Figure 6.6 Lidoderm: Historical Sales ($m, AGR%), 2009-2013
  • Figure 6.7 Lidoderm: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 6.8 Lyrica: Historical Sales ($m, AGR%), 2009-2013
  • Figure 6.9 Lyrica: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 6.10 Cymbalta: Historical Sales ($m, AGR%), 2008-2013
  • Figure 6.11 Cymbalta: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 6.12 Neurontin: Historical Sales ($m, AGR%), 2009-2013
  • Figure 6.13 Neurontin: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 6.14 Nucynta: Historical Sales ($m, AGR%), 2010-2013
  • Figure 6.15 Nucynta: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 6.16 Other Neuropathic Pain Relieving Drugs: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 7.1 The Global Anti-Migraine Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013
  • Figure 7.2 The Global Anti-Migraine Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.3 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013
  • Figure 7.4 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2018
  • Figure 7.5The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2024
  • Figure 7.6 Relpax: Historical Sales ($m, AGR%), 2009-2013
  • Figure 7.7 Relpax: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 7.8 Maxalt: Historical Sales ($m, AGR%), 2008-2013
  • Figure 7.9 Maxalt: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 7.10 Imitrex/Imigran: Historical Sales (£m, AGR%), 2008-2013
  • Figure 7.11 Imitrex/Imigran: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 7.12 Zomig: Historical Sales ($m, AGR%), 2009-2013
  • Figure 7.13 Zomig: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 7.14 Botox (Allergan): Historical Sales ($m, AGR%), 2009-2013
  • Figure 7.15 Botox: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 7.16 Treximet: Historical Sales ($m, AGR%), 2008-2013
  • Figure 7.17 Treximet: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 7.18 Axert: Historical Sales ($m, AGR%), 2011-2013
  • Figure 7.19 Axert: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 7.20 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 8.1 The Global Anti-Arthritic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013
  • Figure 8.2 The Global Anti-Arthritis Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 8.3 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013
  • Figure 8.4 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2018
  • Figure 8.5 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by leading Drugs, 2024
  • Figure 8.6 Humira: Historical Sales ($m), 2008-2013
  • Figure 8.7 Humira: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 8.8 Enbrel: Historical Sales ($m) by Company, 2008-2013
  • Figure 8.9 Enbrel: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 8.10 Remicade: Historical Sales ($m) by Company, 2008-2013
  • Figure 8.11 Remicade: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 8.12 Voltaren: Historical Sales ($m), 2008-2013
  • Figure 8.13 Voltaren: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 8.14 Rituxan: Historical Sales ($m), 2008-2013
  • Figure 8.15 Rituxan: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 8.16 Celebrex: Historical Sales ($m), 2008-2013
  • Figure 8.17 Celebrex: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 8.18 Arcoxia: Historical Sales ($m), 2008-2013
  • Figure 8.19 Arcoxia: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 8.20 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 9.1 The Global Pain Relieving Drugs Market: Market Size ($m) by Region, 2013
  • Figure 9.2 US, EU5, Japan, and South Korea Pain Relieving Drugs Market: Market Forecast ($m), 2013-2024
  • Figure 9.3 Brazil, Russia, India, China, and Turkey Pain Relieving Drugs Markets: Market Forecasts ($m), 2013-2024
  • Figure 9.4 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2013-2018
  • Figure 9.5 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2018-2024
  • Figure 9.6 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2013-2024
  • Figure 9.7 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2013
  • Figure 9.8 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2018
  • Figure 9.9 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2024
  • Figure 9.10 US Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.11 The EU5 Pain Relieving Drugs Market: Revenues ($m) by Country, 2013
  • Figure 9.12 Germany, France, UK, Italy, and Spain Pain Relieving Drugs Market: Market Forecast ($m), 2013-2024
  • Figure 9.13 The EU5 Pain Relieving Drugs Market: Market Shares (%) by Country, 2013
  • Figure 9.14 The EU5 Pain Relieving Drugs Market: Market Shares (%) by Country, 2018
  • Figure 9.15 The EU5 Pain Relieving Drugs Market: Market Shares (%) by Country, 2024
  • Figure 9.16 German Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.17 The UK Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.18 French Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.19 Italian Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.20 Spanish Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.21 Japanese Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.22 Chinese Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.23 South Korean Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.24 Brazilian Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.25 Indian Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.26 Russian Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.27 Turkish Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.28 Rest of the World Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 11.1 Global Population Forecast: Total Population (bn) and Over-65 Population (bn), 2012, 2015, 2018, 2023
  • Figure 13.1 Pain Relieving Drugs: Market Forecast ($m), 2013, 2018, 2021, 2024
  • Figure 13.2 Pain Relieving Drugs: Market Forecast ($m) by Sector, 2013-2024

Companies Listed

  • AB Science
  • Abbott Laboratories
  • AcelRx Pharmaceuticals
  • Actavis (Watson)
  • Acura
  • Afferent Pharmaceuticals
  • Alkem Laboratories
  • Allergan
  • Almirall
  • AlphaPharm
  • Alza Corporation
  • Amgen
  • Aoxing Pharmaceutical Company Inc
  • Apotex Corp
  • Arcion Therapeutics
  • Ascend Laboratories
  • AstraZeneca
  • Avanir
  • Bayer
  • Biodelivery Sciences
  • Biogen Idec
  • Boston Millennia Partners
  • Brigham Young University (BYU)
  • Bristol-Myers Squibb
  • Care Capital
  • Celltrion
  • CeNeS
  • Centocor Ortho Biotech (J&J)
  • Chugai
  • Cilag GmbH International (J&J)
  • CK Life Sciences
  • Collegium
  • CoLucid Pharmaceuticals
  • Convergence Pharmaceuticals
  • Depomed
  • Domain Associates
  • Dr Reddy's Laboratories
  • Durect
  • Eisai
  • Eli Lilly
  • Endo Pharmaceuticals
  • Eurocept BV
  • Exemplar Pharma
  • Forest Laboratories
  • Frazer Healthcare Ventures
  • Galen
  • Genentech (Roche)
  • Genmab
  • Gilead Sciences
  • GlaxoSmithKline
  • Grunenthal Group
  • Horizon Pharma
  • Hospira
  • Human Genome Sciences
  • Immune Pharmaceuticals
  • Impax Laboratories
  • Insys Therapeutics
  • IVAX Pharmaceuticals
  • Janssen Pharmaceuticals
  • Johnson&Johnson
  • Kaiser Foundation Health Plan Inc
  • King Pharmaceuticals (Pfizer)
  • Kyorin
  • Longitude Capital
  • Lundbeck
  • Lupin Pharmaceuticals
  • McNeil Consumer Healthcare (J&J)
  • Merck & Co.
  • Merck Serono
  • Mitsubishi Tanabe Pharma
  • Monsanto
  • Mylan
  • Nektar Therapeutics
  • NeurAxon Inc
  • NeurogesX
  • Neurotune
  • Newron Pharmaceuticals
  • NicOx
  • Novartis
  • NuPathe (Teva)
  • Nuvo Research
  • Omeros
  • Ono Pharmaceuticals
  • Ortho-McNeil-Janssen Pharmaceuticals
  • Pacira Pharmaceuticals
  • Pain Therapeutics
  • Paion
  • Pappas Ventures
  • Par Pharmaceutical
  • Pearl Street Venture Funds
  • Penwest Pharmaceuticals
  • Pernix Therapeutics Holding Inc
  • Pfizer
  • Pharmacia
  • PLx Pharma
  • Pozen Pharmaceuticals
  • Proteus SA
  • Purdue Pharma
  • QRx Pharma
  • Ranbaxy
  • Ratiopharm
  • Rinat (Pfizer)
  • Roche
  • Roxane Laboratories
  • Sandoz (Novartis)
  • Sanofi
  • Schering-Plough (Merck & Co)
  • Shionogi & Co Ltd
  • Shire
  • Skye Pharma
  • Skyline Ventures
  • Spinifex Pharmaceuticals
  • Stada Arzneimittel AG
  • Syntaxin
  • Takeda
  • Teikoku
  • Teva
  • Triathlon Medical Ventures
  • UCB
  • US WorldMeds
  • Valeant
  • Watson Pharmaceuticals
  • WEX Pharmaceuticals
  • Zars Pharmaceuticals (Nuvo Research)
  • Zogenix

Organisations Mentioned In The Report

  • Boston Children Hospital [US]
  • Center for Medicare and Medicaid Services
  • Committee for Medicinal Products for Human Use (CHMP)
  • European Commission
  • Federal Drug Control Service [Russia]
  • International Association for the Study of Pain (IASP)
  • National Institute for Health and Care Excellence (NICE)
  • The American Pain Society
  • The Arthritis Foundation
  • The International Diabetes Federation
  • The National Institute for Population and Social Security Research (IPSS) [Japan]
  • US Census Bureau
  • US Food and Drug Administration (FDA)
  • US Justice Department
  • US Patent and Trademark Office
  • US Society for Neuroscience
  • World Health Organisation (WHO)
Back to Top